353 related articles for article (PubMed ID: 36647827)
21. Targeting IDH1/IDH2 mutations in gliomas.
de la Fuente MI
Curr Opin Neurol; 2022 Dec; 35(6):787-793. PubMed ID: 36367045
[TBL] [Abstract][Full Text] [Related]
22. R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition.
Sears TK; Woolard KD
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2275-2285. PubMed ID: 35467128
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice.
Kadiyala P; Carney SV; Gauss JC; Garcia-Fabiani MB; Haase S; Alghamri MS; Núñez FJ; Liu Y; Yu M; Taher A; Nunez FM; Li D; Edwards MB; Kleer CG; Appelman H; Sun Y; Zhao L; Moon JJ; Schwendeman A; Lowenstein PR; Castro MG
J Clin Invest; 2021 Feb; 131(4):. PubMed ID: 33332283
[TBL] [Abstract][Full Text] [Related]
24. Transcriptional alterations in glioma result primarily from DNA methylation-independent mechanisms.
Court F; Le Boiteux E; Fogli A; Müller-Barthélémy M; Vaurs-Barrière C; Chautard E; Pereira B; Biau J; Kemeny JL; Khalil T; Karayan-Tapon L; Verrelle P; Arnaud P
Genome Res; 2019 Oct; 29(10):1605-1621. PubMed ID: 31533980
[TBL] [Abstract][Full Text] [Related]
25. Alternative lengthening of telomeres is the major telomere maintenance mechanism in astrocytoma with isocitrate dehydrogenase 1 mutation.
Ferreira MSV; Sørensen MD; Pusch S; Beier D; Bouillon AS; Kristensen BW; Brümmendorf TH; Beier CP; Beier F
J Neurooncol; 2020 Mar; 147(1):1-14. PubMed ID: 31960234
[TBL] [Abstract][Full Text] [Related]
26. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
27. IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression.
Zhang X; Rao A; Sette P; Deibert C; Pomerantz A; Kim WJ; Kohanbash G; Chang Y; Park Y; Engh J; Choi J; Chan T; Okada H; Lotze M; Grandi P; Amankulor N
Neuro Oncol; 2016 Oct; 18(10):1402-12. PubMed ID: 27116977
[TBL] [Abstract][Full Text] [Related]
28. Emerging interplay of genetics and epigenetics in gliomas: a new hope for targeted therapy.
Yong RL; Tsankova NM
Semin Pediatr Neurol; 2015 Mar; 22(1):14-22. PubMed ID: 25976256
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic Modifications in Tumor-Associated Macrophages: A New Perspective for an Old Foe.
Niu Y; Chen J; Qiao Y
Front Immunol; 2022; 13():836223. PubMed ID: 35140725
[TBL] [Abstract][Full Text] [Related]
30. IDH mutation in glioma: new insights and promises for the future.
Turkalp Z; Karamchandani J; Das S
JAMA Neurol; 2014 Oct; 71(10):1319-25. PubMed ID: 25155243
[TBL] [Abstract][Full Text] [Related]
31. To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.
Bhavya B; Anand CR; Madhusoodanan UK; Rajalakshmi P; Krishnakumar K; Easwer HV; Deepti AN; Gopala S
Cell Mol Neurobiol; 2020 Jan; 40(1):53-63. PubMed ID: 31485826
[TBL] [Abstract][Full Text] [Related]
32. Cancer metabolism as a central driving force of glioma pathogenesis.
Masui K; Cavenee WK; Mischel PS
Brain Tumor Pathol; 2016 Jul; 33(3):161-8. PubMed ID: 27295313
[TBL] [Abstract][Full Text] [Related]
33. Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas.
Al-Ali R; Bauer K; Park JW; Al Abdulla R; Fermi V; von Deimling A; Herold-Mende C; Mallm JP; Herrmann C; Wick W; Turcan Ş
Acta Neuropathol Commun; 2019 Dec; 7(1):201. PubMed ID: 31806013
[TBL] [Abstract][Full Text] [Related]
34. Mutant ATRX: uncovering a new therapeutic target for glioma.
Haase S; Garcia-Fabiani MB; Carney S; Altshuler D; Núñez FJ; Méndez FM; Núñez F; Lowenstein PR; Castro MG
Expert Opin Ther Targets; 2018 Jul; 22(7):599-613. PubMed ID: 29889582
[TBL] [Abstract][Full Text] [Related]
35. Radiation-induced gliomas: a report of four cases and analysis of molecular biomarkers.
Nakao T; Sasagawa Y; Nobusawa S; Takabatake Y; Sabit H; Kinoshita M; Miyashita K; Hayashi Y; Yokoo H; Nakada M
Brain Tumor Pathol; 2017 Oct; 34(4):149-154. PubMed ID: 28795231
[TBL] [Abstract][Full Text] [Related]
36. Advances in the Immunotherapeutic Potential of Isocitrate Dehydrogenase Mutations in Glioma.
Tang F; Pan Z; Wang Y; Lan T; Wang M; Li F; Quan W; Liu Z; Wang Z; Li Z
Neurosci Bull; 2022 Sep; 38(9):1069-1084. PubMed ID: 35670952
[TBL] [Abstract][Full Text] [Related]
37. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
[TBL] [Abstract][Full Text] [Related]
38. Glioma epigenetics: From subclassification to novel treatment options.
Gusyatiner O; Hegi ME
Semin Cancer Biol; 2018 Aug; 51():50-58. PubMed ID: 29170066
[TBL] [Abstract][Full Text] [Related]
39. Global DNA Methylation Patterns in Human Gliomas and Their Interplay with Other Epigenetic Modifications.
J Dabrowski M; Wojtas B
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31311166
[TBL] [Abstract][Full Text] [Related]
40. IDH1 mutant glioma is preferentially sensitive to the HDAC inhibitor panobinostat.
Sears TK; Horbinski CM; Woolard KD
J Neurooncol; 2021 Sep; 154(2):159-170. PubMed ID: 34424450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
